Kilitch Drugs (India) Limited vs Laurus Labs Limited
A side-by-side comparison of Kilitch Drugs (India) Limited (KILITCH) and Laurus Labs Limited (LAURUSLABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Laurus Labs Limited leads KILITCH vs LAURUSLABS on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
LAURUSLABS takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
KILITCH takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LAURUSLABS takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 49.1% CAGR over last 5 years", "Company has delivered good sales growth of 28.2% CAGR over last 5 years"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend"]
- + []
- − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.